What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies

In this review we examine, in the context of the amyloid, tau, and neurodegeneration framework, the available evidence and potential alternatives on how to establish tau positivity (T+) for multiple tau-imaging tracers in order to reach a consensus on normal and abnormal tau imaging values that can be universally implemented in clinical research and therapeutic trials.

[1]  Muhammad Naveed Iqbal Qureshi,et al.  18F-MK-6240 PET for early and late detection of neurofibrillary tangles. , 2020, Brain : a journal of neurology.

[2]  O. Hansson,et al.  Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders , 2020, JAMA neurology.

[3]  Val J Lowe,et al.  Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. , 2020, JAMA neurology.

[4]  W. Jagust,et al.  Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults , 2020, Neurology.

[5]  Jesse A. Brown,et al.  Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET , 2020, Science Translational Medicine.

[6]  Lisa Delano-Wood,et al.  Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity , 2019, Brain communications.

[7]  M. Gorno-Tempini,et al.  Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease , 2019, Alzheimer's & Dementia.

[8]  Keith A. Johnson,et al.  Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease , 2019, JAMA neurology.

[9]  William J. Jagust,et al.  Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span , 2019, The Journal of Nuclear Medicine.

[10]  F. Bray,et al.  Essential TNM: a registry tool to reduce gaps in cancer staging information. , 2019, The Lancet. Oncology.

[11]  Sterling C. Johnson,et al.  In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls , 2018, The Journal of Nuclear Medicine.

[12]  A. Fagan,et al.  Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging , 2018, Alzheimer's & Dementia.

[13]  B. Miller,et al.  Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders , 2018, JAMA.

[14]  O Almkvist,et al.  Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia , 2018, Molecular Psychiatry.

[15]  Bradley T. Christian,et al.  The use of Centiloids for applying [11C]PiB classification cutoffs across region-of-interest delineation methods , 2018, Alzheimer's & dementia.

[16]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[17]  Christopher G Schwarz,et al.  Longitudinal tau PET in ageing and Alzheimer’s disease , 2018, Brain : a journal of neurology.

[18]  Shannon L. Risacher,et al.  Topographic staging of tau positron emission tomography images , 2018, Alzheimer's & dementia.

[19]  W. Klunk.  Molecular imaging: What is right and what is an illusion? , 2018, Alzheimer's & dementia.

[20]  Gil D Rabinovici,et al.  Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample , 2017, Neurology.

[21]  Christopher C Rowe,et al.  Biochemically-defined pools of amyloid-&bgr; in sporadic Alzheimer’s disease: correlation with amyloid PET , 2017, Brain : a journal of neurology.

[22]  O. Hansson,et al.  Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks , 2017, Frontiers in Neuroscience.

[23]  S. Gauthier,et al.  Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain , 2017, Alzheimer's Research & Therapy.

[24]  David T. Jones,et al.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.

[25]  M. Mintun,et al.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition , 2017, Brain : a journal of neurology.

[26]  Clifford R. Jack,et al.  Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition , 2016, Alzheimer's & dementia.

[27]  Clifford R. Jack,et al.  An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.

[28]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[29]  Lennart Thurfjell,et al.  The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data , 2015, Alzheimer's & Dementia.

[30]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[31]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[32]  R. Palmer,et al.  Modeling regional vulnerability to Alzheimer pathology , 2012, Neurobiology of Aging.

[33]  Clifford R Jack,et al.  Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.

[34]  W. Jagust.  Amyloid imaging: liberal or conservative? Let the data decide. , 2011, Archives of neurology.

[35]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[36]  A. Delacourte,et al.  The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease , 1999, Neurology.

[37]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[38]  K. Blennow,et al.  Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force , 2019, The Journal of Prevention of Alzheimer's Disease.

[39]  M. Mintun,et al.  Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging. , 2019, Journal of Alzheimer's disease : JAD.

[40]  C. Rowe,et al.  Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease using Cerebrospinal Fluid Biomarkers in the AIBL Study , 2019, The Journal of Prevention of Alzheimer's Disease.

[41]  A. Huxley.  Ends and means : an inquiry into the nature of ideals and into the methods employed for their realization , 1946 .